Information, Community and Research Funding

The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.



Signup for our email newsletter below to hear about the latest research, fundraisers and events. Follow us on Facebook. Don’t forget to hit that Like button!


Donate and encourage others to donate as well. Attend and support one of the fundraising events held each year. To view the funding needed see our Current Research Page


Share the EHE Foundation with the world. Let them know that we are here and that we need funding to fight EHE. Tell them your story and encourage them to help.


The Pledge, Edition 11

We warmly welcome all our readers to this eleventh edition of “The Pledge”, the quarterly newsletter of the EHE Group. We hope you enjoy this newsletter, covering the fourth quarter of 2017.


Trametinib Trial

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery. Identifier:  NCT03148275

For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction. During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.

The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrollment in different parts of the country. You can see more information using following link.

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Identifier: NCT03331250

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.

Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules


Justin Bryan Featured

Justin Bryan is One Tuff Dude

In October of 2015, Justin Bryan endured a 10-day trek up 19,341 feet of elevation as he scaled the peak of Mount Kilimanjaro in Tanzania. Not too shabby for a man who was told 12…

Learn More
Mandy and Devin O'Connor

Mandy O’Connor

Mandy O’Connor, a York native, Penn State graduate, and THON participant, fought Epithelioid Hemangioendothelioma (EHE) for more than a decade. EHE is a rare and often deadly vascular sarcoma (cancer) that largely affects adolescents and…

Learn More
Ava Featured Image

Ava’s Story

Ava is an eight year old girl from Langhorne, PA, where Sesame Place is located. We are about 25 miles from Center City Philadelphia. Ava loves swimming and going to Sesame Place, since it is…

Learn More